TLR7 and leukemia: In this first‐in‐human phase I trial, TLR7/8‐matured DCs transfected with RNA encoding two leukaemia‐associated antigens (WT1 and PRAME) and CMVpp65 were used as post‐remission therapy for AML patients at high risk of relapse.